Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NMTR NASDAQ:SPRC NASDAQ:TFFP NASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs14 shsSPRCSciSparc$1.80-0.6%$5.04$1.75▼$37.59$970K0.861.04 million shs117,195 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289KN/AN/AN/AZVSAZyVersa Therapeutics$0.18+16.6%$0.22$0.11▼$3.37$1.42M0.733.07 million shs129,319 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNMTR9 Meters Biopharma0.00%0.00%0.00%-99.72%-81.82%SPRCSciSparc-0.55%-19.28%-60.09%-72.17%-71.43%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-97.06%ZVSAZyVersa Therapeutics+16.59%+17.98%+15.61%-72.11%-91.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs14 shsSPRCSciSparc$1.80-0.6%$5.04$1.75▼$37.59$970K0.861.04 million shs117,195 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289KN/AN/AN/AZVSAZyVersa Therapeutics$0.18+16.6%$0.22$0.11▼$3.37$1.42M0.733.07 million shs129,319 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNMTR9 Meters Biopharma0.00%0.00%0.00%-99.72%-81.82%SPRCSciSparc-0.55%-19.28%-60.09%-72.17%-71.43%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-97.06%ZVSAZyVersa Therapeutics+16.59%+17.98%+15.61%-72.11%-91.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNMTR9 Meters Biopharma 0.00N/AN/AN/ASPRCSciSparc 0.00N/AN/AN/ATFFPTFF Pharmaceuticals 0.00N/AN/AN/AZVSAZyVersa Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ASPRCSciSparc$1.31M0.73N/AN/A$18.13 per share0.10TFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02ZVSAZyVersa TherapeuticsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ASPRCSciSparc-$6.28MN/A0.00∞N/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals-$21.24M-$6.44N/A∞N/AN/AN/AN/AN/AZVSAZyVersa Therapeutics-$9.41MN/A0.00N/AN/AN/A-109.54%-43.95%11/13/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNMTR9 Meters BiopharmaN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNMTR9 Meters BiopharmaN/A0.590.59SPRCSciSparcN/A5.365.28TFFPTFF PharmaceuticalsN/AN/AN/AZVSAZyVersa TherapeuticsN/A0.180.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNMTR9 Meters Biopharma22.34%SPRCSciSparc25.06%TFFPTFF Pharmaceuticals15.25%ZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipNMTR9 Meters Biopharma2.40%SPRCSciSparc1.52%TFFPTFF Pharmaceuticals4.50%ZVSAZyVersa Therapeutics0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataSPRCSciSparc4530,000527,000Not OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableZVSAZyVersa Therapeutics27.94 million4.86 millionNot OptionableTFFP, ZVSA, NMTR, and SPRC HeadlinesRecent News About These CompaniesZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term ...September 10, 2025 | markets.businessinsider.comZyVersa Therapeutics Highlights Role of Inflammasomes in Type 2 Diabetes and Cardiovascular Complications with Promising Data on IC 100September 10, 2025 | quiverquant.comQZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular OutcomesSeptember 10, 2025 | globenewswire.comZyVersa Therapeutics highlights lipidomic data in Alport Syndrome, DKDSeptember 3, 2025 | msn.comZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease ...September 3, 2025 | finance.yahoo.comZyVersa Therapeutics Initiates Phase 2a Clinical Trial for Cholesterol Efflux Mediator™ VAR 200 in Diabetic Kidney Disease PatientsSeptember 3, 2025 | quiverquant.comQZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease ProgressionSeptember 3, 2025 | globenewswire.comZyVersa Therapeutics Reports Financial Challenges Amid Nasdaq DelistingAugust 20, 2025 | msn.comZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last yearAugust 14, 2025 | msn.comZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address ...August 14, 2025 | bakersfield.comBZyVersa Therapeutics highlights data on role of lipotoxicity in DKDAugust 14, 2025 | msn.comZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its ProgressionAugust 14, 2025 | globenewswire.comZyVersa Therapeutics Activates First Clinical Site for Phase 2a Trial of VAR 200 in Diabetic Kidney Disease and Reports Progress in Product DevelopmentAugust 13, 2025 | quiverquant.comQZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building MilestonesAugust 13, 2025 | globenewswire.comZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D ProgressJuly 21, 2025 | globenewswire.comZyVersa Touches 52-Week Low; Nasdaq to Suspend Trading ThursdayJuly 16, 2025 | marketwatch.comZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds | MorningstarJuly 9, 2025 | morningstar.comMZyVersa’s VAR 200 approved for emergency use in rare kidney diseaseJuly 9, 2025 | uk.investing.comZyVersa Therapeutics Supports Emergency Compassionate Use of VAR 200 for Patient with ApoCII Amyloidosis - NasdaqJuly 9, 2025 | nasdaq.comWhy Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?July 8, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTFFP, ZVSA, NMTR, and SPRC Company Descriptions9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.SciSparc NASDAQ:SPRC$1.80 -0.01 (-0.55%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.77 -0.03 (-1.67%) As of 09/15/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.TFF Pharmaceuticals NASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.ZyVersa Therapeutics NASDAQ:ZVSA$0.18 +0.03 (+16.59%) As of 09/15/2025 03:46 PM EasternZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
